{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-16T03:54:18.033146+00:00","published_at":"2026-10-15T04:45:20.170332+00:00","section":"events","data":{"state":"PUBLISHED","derivation_version":"alpha-governance-event-derivation-v2","events":[{"event_id":"alpha:event:transition:1jslq8114ry86d","event_type":"GC_CHANGED","effective_at":"2026-02-11","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:arthur-mcgivern","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:46f466c145a6f4561c39e1d47b3dda5343264b1cf17411ddfa1973745fce9413"],"summary":"Arthur McGivern executive of Royalty Pharma plc, effective 2026-02-11.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1x46hfmwfkqe2","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-02-11","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:christopher-hite","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:32fdb41ecd90c2bf5b37736ef3269e114d86ee7cb712247f6773cead527f4e6b"],"summary":"Christopher Hite executive of Royalty Pharma plc, effective 2026-02-11.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1v69wwsusmf3o","event_type":"CEO_CHANGED","effective_at":"2026-02-11","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:pablo-legorreta","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:13"],"evidence_ids":["alpha:projection-evidence:document:fc239e7f7d25570af850be68f8f96d34964d86026f437b073382d6dce23373a9"],"summary":"Pablo Legorreta executive of Royalty Pharma plc, effective 2026-02-11.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1lcgz5m1oip6ni","event_type":"CFO_CHANGED","effective_at":"2026-02-11","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:terrance-coyne","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:14"],"evidence_ids":["alpha:projection-evidence:document:7c957b70fb9f13dac90b192ae1ddb29380147c09225a7c3dd4548db6f3211f1b"],"summary":"Terrance Coyne executive of Royalty Pharma plc, effective 2026-02-11.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:xk69ms1nwf2r4","event_type":"DIRECTOR_APPOINTED","effective_at":"2025-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:vlad-coric-m-d-bhvn","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:10"],"evidence_ids":["alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7"],"summary":"Vlad Coric, M.D. seat on Royalty Pharma plc, effective 2025-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:8ux7l98efc15","event_type":"DIRECTOR_APPOINTED","effective_at":"2022-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:david-hodgson","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7"],"summary":"David Hodgson seat on Royalty Pharma plc, effective 2022-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:elldo91ty7vy1","event_type":"COMMITTEE_CREATED","effective_at":"2022-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:committee:royalty-pharma-plc:audit-compensation-chair","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7"],"summary":"Audit; Compensation · Chair committee of Royalty Pharma plc, effective 2022-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1kfiade1w40ots","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2022-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:david-hodgson","alpha:committee:royalty-pharma-plc:audit-compensation-chair"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7"],"summary":"David Hodgson member of Audit; Compensation · Chair, effective 2022-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:ykjzte642uqi","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:catherine-engelbert","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7"],"summary":"Catherine Engelbert seat on Royalty Pharma plc, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1yx0s7cnp2gek","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:gregory-norden","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7"],"summary":"Gregory Norden seat on Royalty Pharma plc, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:80oqcd1a9341h","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:pablo-legorreta-2","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:9"],"evidence_ids":["alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7"],"summary":"Pablo Legorreta seat on Royalty Pharma plc, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:nnaa8ckhpvvq","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2020-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:catherine-engelbert","alpha:committee:royalty-pharma-plc:audit"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:committee_record:15"],"evidence_ids":["alpha:projection-evidence:e1dd164a848b2c7ec7f14ef97c50d743a992f57e8da6f49d1b4e28b34da58d02"],"summary":"Catherine Engelbert member of Audit, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:y827py1d3svuw","event_type":"COMMITTEE_CREATED","effective_at":"2020-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:committee:royalty-pharma-plc:audit-chair-nominating-and-governance","alpha:company:52361b75-63da-4409-82b1-fed172f2f056"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7"],"summary":"Audit · Chair; Nominating and Governance committee of Royalty Pharma plc, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:wuavji1azfwqe","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2020-01-01","detected_at":"2026-10-15T04:45:20.170332+00:00","subject_ids":["alpha:person:gregory-norden","alpha:committee:royalty-pharma-plc:audit-chair-nominating-and-governance"],"caused_claim_ids":["alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7"],"summary":"Gregory Norden member of Audit · Chair; Nominating and Governance, effective 2020-01-01.","derivation":"temporal_relationship_change"}]},"claims":[{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:6","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:catherine-engelbert","object_label":"Catherine Engelbert","object_source_name_forms":[],"value":"Catherine Engelbert: Director, Audit","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:catherine-engelbert","name":"Catherine Engelbert"},"title":"Director","role_category":"director","committee":"Audit","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Royalty Pharma plc DEF 14A 2026-04-10","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000114036126014239/ny20066979x1_def14a.htm","source_date":"2026-04-10","retrieved_at":"2026-07-12T04:22:07.189599+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-10","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:7","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:david-hodgson","object_label":"David Hodgson","object_source_name_forms":[],"value":"David Hodgson: Director, Audit; Compensation · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:david-hodgson","name":"David Hodgson"},"title":"Director","role_category":"director","committee":"Audit; Compensation · Chair","is_board_chair":false,"is_independent":true,"start_date":"2022-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2022-01-01","valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Royalty Pharma plc DEF 14A 2026-04-10","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000114036126014239/ny20066979x1_def14a.htm","source_date":"2026-04-10","retrieved_at":"2026-07-12T04:22:07.189599+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-10","effective_from":"2022-01-01","effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:8","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:gregory-norden","object_label":"Gregory Norden","object_source_name_forms":[],"value":"Gregory Norden: Director, Audit · Chair; Nominating and Governance","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:gregory-norden","name":"Gregory Norden"},"title":"Director","role_category":"director","committee":"Audit · Chair; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Royalty Pharma plc DEF 14A 2026-04-10","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000114036126014239/ny20066979x1_def14a.htm","source_date":"2026-04-10","retrieved_at":"2026-07-12T04:22:07.189599+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-10","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:9","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:pablo-legorreta-2","object_label":"Pablo Legorreta","object_source_name_forms":[],"value":"Pablo Legorreta: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:pablo-legorreta-2","name":"Pablo Legorreta"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Royalty Pharma plc DEF 14A 2026-04-10","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000114036126014239/ny20066979x1_def14a.htm","source_date":"2026-04-10","retrieved_at":"2026-07-12T04:22:07.189599+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-10","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:10","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:vlad-coric-m-d-bhvn","object_label":"Vlad Coric, M.D.","object_source_name_forms":[],"value":"Vlad Coric, M.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:vlad-coric-m-d-bhvn","name":"Vlad Coric, M.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2025-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2025-01-01","valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Royalty Pharma plc DEF 14A 2026-04-10","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000114036126014239/ny20066979x1_def14a.htm","source_date":"2026-04-10","retrieved_at":"2026-07-12T04:22:07.189599+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-04-10","effective_from":"2025-01-01","effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:11","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:arthur-mcgivern","object_label":"Arthur McGivern","object_source_name_forms":[],"value":"Arthur McGivern: General Counsel","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:arthur-mcgivern","name":"Arthur McGivern"},"title":"General Counsel","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-02-11","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-02-11","valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:document:46f466c145a6f4561c39e1d47b3dda5343264b1cf17411ddfa1973745fce9413","identity_scope":"source_document_reference","source_type":"sec_filing","title":"RPRX 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm","source_date":"2026-02-11T00:00:00+00:00","retrieved_at":"2026-05-05T01:12:27.886785+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-02-11T00:00:00+00:00","effective_from":"2026-02-11","effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:12","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:christopher-hite","object_label":"Christopher Hite","object_source_name_forms":[],"value":"Christopher Hite: Executive Vice President and Vice Chairman","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:christopher-hite","name":"Christopher Hite"},"title":"Executive Vice President and Vice Chairman","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-02-11","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-02-11","valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:document:32fdb41ecd90c2bf5b37736ef3269e114d86ee7cb712247f6773cead527f4e6b","identity_scope":"source_document_reference","source_type":"sec_filing","title":"RPRX 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm","source_date":"2026-02-11T00:00:00+00:00","retrieved_at":"2026-05-05T01:12:27.33944+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-02-11T00:00:00+00:00","effective_from":"2026-02-11","effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:13","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:pablo-legorreta","object_label":"Pablo Legorreta","object_source_name_forms":[],"value":"Pablo Legorreta: Chairman of the Board, Director and Chief Executive Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:pablo-legorreta","name":"Pablo Legorreta"},"title":"Chairman of the Board, Director and Chief Executive Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-02-11","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-02-11","valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:document:fc239e7f7d25570af850be68f8f96d34964d86026f437b073382d6dce23373a9","identity_scope":"source_document_reference","source_type":"sec_filing","title":"RPRX 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm","source_date":"2026-02-11T00:00:00+00:00","retrieved_at":"2026-05-05T01:12:26.291091+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-02-11T00:00:00+00:00","effective_from":"2026-02-11","effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:14","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:terrance-coyne","object_label":"Terrance Coyne","object_source_name_forms":[],"value":"Terrance Coyne: Executive Vice President and Chief Financial Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:terrance-coyne","name":"Terrance Coyne"},"title":"Executive Vice President and Chief Financial Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-02-11","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-02-11","valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:document:7c957b70fb9f13dac90b192ae1ddb29380147c09225a7c3dd4548db6f3211f1b","identity_scope":"source_document_reference","source_type":"sec_filing","title":"RPRX 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm","source_date":"2026-02-11T00:00:00+00:00","retrieved_at":"2026-05-05T01:12:26.797421+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-02-11T00:00:00+00:00","effective_from":"2026-02-11","effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:52361b75-63da-4409-82b1-fed172f2f056:committee_record:15","subject_id":"alpha:company:52361b75-63da-4409-82b1-fed172f2f056","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Audit: Chair Gregory Norden; Members Gregory Norden (Chair); Catherine Engelbert; David Hodgson","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Audit","canonical_type":"audit","chair":"Gregory Norden","members":[{"display_name":"Gregory Norden","person_slug":"gregory-norden","is_chair":true},{"display_name":"Catherine Engelbert","person_slug":"catherine-engelbert","is_chair":false},{"display_name":"David Hodgson","person_slug":"david-hodgson","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-15T04:45:20.170332+00:00","sources":[{"id":"alpha:projection-evidence:e1dd164a848b2c7ec7f14ef97c50d743a992f57e8da6f49d1b4e28b34da58d02","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1802768/000114036126014239/ny20066979x1_def14a.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:e021c23c7bd560137e2bbc66332ea014e88beb22b05e75ce7fac92e2d7b857f7","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Royalty Pharma plc DEF 14A 2026-04-10","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000114036126014239/ny20066979x1_def14a.htm","source_date":"2026-04-10","retrieved_at":"2026-07-12T04:22:07.189599+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:46f466c145a6f4561c39e1d47b3dda5343264b1cf17411ddfa1973745fce9413","identity_scope":"source_document_reference","source_type":"sec_filing","title":"RPRX 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm","source_date":"2026-02-11T00:00:00+00:00","retrieved_at":"2026-05-05T01:12:27.886785+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:32fdb41ecd90c2bf5b37736ef3269e114d86ee7cb712247f6773cead527f4e6b","identity_scope":"source_document_reference","source_type":"sec_filing","title":"RPRX 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm","source_date":"2026-02-11T00:00:00+00:00","retrieved_at":"2026-05-05T01:12:27.33944+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:fc239e7f7d25570af850be68f8f96d34964d86026f437b073382d6dce23373a9","identity_scope":"source_document_reference","source_type":"sec_filing","title":"RPRX 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm","source_date":"2026-02-11T00:00:00+00:00","retrieved_at":"2026-05-05T01:12:26.291091+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:7c957b70fb9f13dac90b192ae1ddb29380147c09225a7c3dd4548db6f3211f1b","identity_scope":"source_document_reference","source_type":"sec_filing","title":"RPRX 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm","source_date":"2026-02-11T00:00:00+00:00","retrieved_at":"2026-05-05T01:12:26.797421+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:e1dd164a848b2c7ec7f14ef97c50d743a992f57e8da6f49d1b4e28b34da58d02","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1802768/000114036126014239/ny20066979x1_def14a.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.835,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.852,"cross_source_agreement":0.75,"temporal_completeness":0.643},"diagnostics":{"published_claims":22,"factual_claims":22,"claims_with_linked_evidence":22,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":14,"temporal_claims_with_valid_from":9,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-15T04:45:20.170332+00:00","observed_at":"2026-10-15T04:45:20.170332+00:00","reviewed_at":"2026-10-15T04:45:20.170332+00:00","verified_at":"2026-10-15T04:45:20.170332+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":22,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/royalty-pharma-plc/events","section":"events","href":"https://registry.alpha.ac/api/public/companies/royalty-pharma-plc?format=record&section=events","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}